Hodgkin Lymphoma
ctDNA MRD Monitoring with Strong Prognostic Value; Molecular Profiling Identifies Checkpoint Inhibitor Sensitivity
Clinical Overview
Classical Hodgkin lymphoma (cHL) is characterized by sparse malignant Hodgkin-Reed-Sternberg (HRS) cells comprising only 0.1-10% of the tumor mass, embedded within extensive reactive inflammatory infiltrates. This unique biology creates technical challenges for ctDNA detection but yields powerful prognostic information when successful.
ctDNA testing serves two distinct clinical roles in Hodgkin lymphoma: MRD monitoring after treatment and molecular profiling for genotype-directed therapy selection. MRD detection demonstrates 92-97% baseline sensitivity and provides exceptional prognostic stratification, with hazard ratios ranging from 6.9 to 8.7 depending on timepoint. The HD21 trial substudy demonstrated that MRD-positive patients after 2 cycles of therapy have 6.9-fold higher risk of progression compared to MRD-negative patients (4-year PFS: 72.2% vs 95.3%, p < 0.0001).
Beyond MRD, molecular profiling reveals near-universal 9p24.1 amplification (100% of cases) affecting PD-L1, PD-L2, and JAK2, creating sensitivity to checkpoint inhibitors with 69-87% objective response rates. JAK/STAT pathway mutations occur in over 90% of cases, and genomic subtyping identifies two major subtypes (H1: 68%, H2: 32%) with distinct biological characteristics.
Why ctDNA Matters in Hodgkin Lymphoma
- MRD prognostic power: HR 5.3 after 2 cycles (HD21 full publication, Blood 2026: 4-year PFS 82.2% MRD- vs 36.7% MRD+)
- High sensitivity: 92-97% baseline detection; 93.8% using targeted sequencing approaches
- Molecular clearance precedes imaging: Earlier detection than PET-CT
- 9p24.1 amplification: 100% of cases; enables checkpoint inhibitor therapy (nivolumab: 87% ORR phase 1; pembrolizumab: 69% ORR)
- JAK/STAT alterations: >90% prevalence; ruxolitinib + nivolumab achieves 53% ORR
- Genomic subtypes: H1 (68%) vs H2 (32%) with distinct characteristics
ctDNA Testing Methodology
Hodgkin Lymphoma ctDNA Detection
Hodgkin-Specific Considerations:
- Baseline sensitivity: 92-97% detection rate
- Enables tracking of sparse HRS cell-derived ctDNA despite the low tumor cell content characteristic of Hodgkin lymphoma (HRS cells typically comprise only 1-2% of the tumor mass)
- Identifies patient-specific immunoglobulin gene rearrangements or somatic mutations
LIQOMICS Testing Solutions for Hodgkin Lymphoma
LymphoVista offers tumor-informed ctDNA testing for Hodgkin Lymphoma using either baseline tissue or baseline plasma samples for mutation profiling, followed by longitudinal MRD monitoring.
Key Features:
- Works with baseline tissue biopsy or baseline blood draw for initial profiling
- Tracks patient-specific mutations for high-sensitivity MRD detection
- Serial monitoring optimized for lymphoma biology
- Non-invasive blood-based surveillance
- Comprehensive genotyping and mutational profiling
MRD Detection: Clinical Utility
Detection Performance
Clinical Context: Despite low HRS cell content (0.1-10%), modern ctDNA approaches achieve high baseline detection rates through tumor-informed tracking strategies.
Baseline Detection Performance:
- Overall sensitivity: 92-97% at diagnosis
- Targeted sequencing approach: 93.8% detection using CAPP-seq methodology
- Detection challenge: Low tumor cellularity requires highly sensitive methods
- Technical consideration: Clonal hematopoiesis (CHIP) interferes in 33% of cases
Reference: Spina V et al. Blood 2018;131:2413-2425
Prognostic Value: HD21 Trial MRD Substudy
Clinical Context: The HD21 trial MRD substudy using the LymphoVista HL assay demonstrated that ctDNA MRD status after 2 cycles of chemotherapy powerfully predicts treatment outcomes in advanced-stage classical Hodgkin lymphoma. Preliminary results were presented at ASH 2024, with the full peer-reviewed publication in Blood (February 2026) confirming these findings.
HD21 MRD Substudy -- Full Publication Results (Heger, Mattlener et al., Blood 2026):
- Patient population: Advanced-stage cHL patients treated in GHSG HD21 trial (BrECADD vs eBEACOPP)
- MRD assessment timepoint: After 2 cycles of chemotherapy (MRD-2)
- MRD-negative patients: 4-year PFS 82.2% (unweighted analysis)
- MRD-positive patients: 4-year PFS 36.7% (unweighted analysis)
- Hazard Ratio: HR 5.3 (95% CI 2.0-13.8; p = 0.0008)
- BrECADD subgroup: MRD-2 strongly prognostic (4-year PFS: 97.4% MRD-negative vs 52.0% MRD-positive; HR 25.4, p < 0.0001)
- Weighted analysis (ASH 2024 preliminary): 4-year PFS 95.3% (MRD-) vs 72.2% (MRD+); HR 6.9
Combined MRD-2 and PET-2 Risk Stratification
The full Blood 2026 publication demonstrated that combining ctDNA MRD-2 with interim PET-2 enables superior risk stratification through identification of three distinct risk groups:
Combined MRD-2 + PET-2 Risk Groups:
- Low risk: MRD-2 negative AND PET-2 negative -- excellent prognosis, potential candidates for treatment de-escalation
- Intermediate risk: Discordant results (MRD-2 positive OR PET-2 positive) -- requires individualized assessment
- High risk: MRD-2 positive AND PET-2 positive -- highest risk of treatment failure, candidates for intensification
Clinical implication: The combination of molecular MRD and metabolic imaging provides more granular risk stratification than either modality alone.
Interpretation: The HD21 substudy demonstrates that ultrasensitive ctDNA MRD assessment after 2 cycles identifies patients at significantly higher relapse risk, supporting consideration of treatment intensification in MRD-positive patients.
References: Mattlener J et al. Blood 2024;144(Supplement 1):4355; Heger JM, Mattlener J et al. Blood 2026. doi:10.1182/blood.2025031089
Hazard Ratios by Timepoint
Clinical Context: The prognostic value of MRD status varies by assessment timepoint, with validated data from the HD21 substudy demonstrating strong prognostic power after 2 cycles of therapy.
| Assessment Timepoint | Hazard Ratio (HR) | Clinical Interpretation | Study |
|---|---|---|---|
| After 2 cycles (MRD-2) | HR 5.3 (95% CI 2.0-13.8) | Early MRD persistence predicts treatment failure; 4-year PFS 36.7% (MRD+) vs 82.2% (MRD-) | HD21 full publication (Heger, Mattlener et al., Blood 2026) |
| End of treatment | HR 8.7 | EOT MRD+ strongly associated with relapse | Spina et al. 2018 |
Clinical Application: The HD21 full publication (Blood 2026) provides Level 1 evidence that MRD assessment after 2 cycles of chemotherapy identifies patients at higher relapse risk. Combined MRD-2 + PET-2 assessment enables three-tier risk stratification, supporting risk-adapted treatment strategies.
ctDNA Complements PET-CT Throughout Treatment
Clinical Context: Recent data demonstrate that ctDNA-MRD provides complementary prognostic information to PET-CT at multiple treatment timepoints, including identification of high-risk patients who achieve imaging complete response but retain detectable molecular disease.
Discordant PET-Negative / MRD-Positive Results (ASH 2024):
- Key finding: Patients achieving PET complete response but retaining detectable ctDNA-MRD have significantly inferior outcomes
- 3-year PFS: PET-negative/MRD-positive patients: 36% vs PET-negative/MRD-negative patients: 89%
- Implication: PET-CT alone misses a substantial subset of patients with residual molecular disease
- Frequency: Interim MRD positivity despite PET CR occurs in a clinically meaningful proportion of patients
Clinical consequence: These data support the addition of ctDNA-MRD assessment even in patients achieving imaging-based complete response, particularly in early-stage and advanced-stage disease.
Lead Time Advantage
Clinical Context: ctDNA MRD clearance occurs earlier than radiographic resolution, providing advance warning of treatment response or resistance.
Molecular vs Radiographic Response:
- ctDNA clearance: Precedes PET-CT normalization by weeks to months
- Early clearance rate: Over 70% of patients achieve undetectable MRD as early as end of cycle 2 when treated with PD-1 inhibitor plus chemotherapy
- Persistent ctDNA: Detects residual disease before radiographic progression
- Clinical utility: Earlier identification of inadequate response may enable treatment modification
Interventional Trials Using ctDNA in Hodgkin Lymphoma
Clinical Context: Multiple trials are now prospectively using ctDNA to guide treatment decisions, marking a transition from prognostic biomarker to decisional tool.
PRECISE-HL Trial (Launched March 2025)
- Design: ctDNA-guided therapy de-escalation in newly diagnosed advanced-stage cHL
- Population: 125 patients planned
- Treatment: Nivolumab + AVD (doxorubicin, vinblastine, dacarbazine)
- Intervention: After 2 cycles, patients with undetectable ctDNA transition to nivolumab monotherapy for 2 cycles after completing only 4 cycles of nivolumab + AVD; patients with detectable ctDNA continue full 6 cycles
- Primary endpoint: 1-year PFS ≥94% in interim ctDNA-negative patients
- Expected ctDNA-negative rate: ~80% (n=100) at cycle 3 day 1
- Sponsors: University of Washington / Fred Hutch Cancer Center with Foresight Diagnostics
Pembrolizumab + GVD with ctDNA-Guided Consolidation (NCT07021989)
- Design: Phase 2, ctDNA-guided ASCT omission in relapsed/refractory cHL
- Population: 38 patients across 6 University of California sites
- Treatment: 2 cycles pembrolizumab + GVD followed by PET and ctDNA-MRD assessment
- Intervention: Patients achieving metabolic CR AND undetectable MRD receive non-transplant consolidation (pembrolizumab +/- involved-site radiation) instead of ASCT
- Significance: First trial using real-time ctDNA sequencing to guide therapy in relapsed/refractory cHL; may enable omission of high-dose chemotherapy and ASCT in select patients
Clinical Recommendation: MRD Monitoring
Current Evidence Level: Prognostic biomarker with exceptional risk stratification (HR 5.3 in full HD21 publication; up to 8.7 at end of treatment)
Potential Applications:
- MRD-negative: May support treatment de-escalation to reduce late toxicities (PRECISE-HL trial testing this approach)
- MRD-positive (especially if PET-negative): Consider treatment intensification, autologous stem cell transplant, or novel therapy enrollment
- Relapsed/refractory setting: ctDNA-guided consolidation may enable ASCT omission in select patients (Pembro-GVD trial)
Important Limitation: ctDNA-guided therapy adaptation is now being tested in prospective interventional trials (PRECISE-HL, Pembro-GVD) but is not yet validated. Current clinical use should focus on risk stratification and clinical trial enrollment.
Genotyping: Clinical Utility
Clinical Context: Molecular profiling of Hodgkin lymphoma reveals near-universal genomic alterations that predict sensitivity to specific targeted therapies, particularly checkpoint inhibitors and JAK inhibitors.
9p24.1 Amplification: PD-L1/PD-L2/JAK2
Clinical Context: The 9p24.1 chromosomal region contains PD-L1, PD-L2, and JAK2 genes. Amplification of this region is a defining molecular feature of classical Hodgkin lymphoma, occurring in 100% of cases and creating exquisite sensitivity to checkpoint blockade.
9p24.1 Amplification Profile:
- Prevalence: 100% of classical HL cases
- Affected genes: PD-L1 (CD274), PD-L2 (PDCD1LG2), JAK2
- Mechanism: Copy number gain leads to PD-L1/PD-L2 overexpression on HRS cells
- Biological consequence: Immune evasion through PD-1/PD-L1 axis activation
- Therapeutic implication: Strong rationale for PD-1 blockade
Checkpoint Inhibitor Therapy
Evidence: PD-1 inhibitors demonstrate exceptional activity in relapsed/refractory Hodgkin lymphoma driven by near-universal 9p24.1 amplification.
| Agent | Objective Response Rate | Complete Response Rate | Clinical Context |
|---|---|---|---|
| Nivolumab (monotherapy) | 87% | 17% | Relapsed/refractory after ASCT (phase 1, n=23) |
| Pembrolizumab (monotherapy) | 69% | 22% | Relapsed/refractory after brentuximab (KEYNOTE-087) |
| Nivolumab + brentuximab vedotin | 85% | 67% | Combination shows synergistic activity |
Clinical Interpretation: The 100% prevalence of 9p24.1 amplification explains the consistently high response rates to checkpoint inhibitors across all Hodgkin lymphoma patients, unlike solid tumors where PD-L1 expression is heterogeneous.
References: Ansell SM et al. N Engl J Med 2015;372:311-319; Chen R et al. J Clin Oncol 2017;35:2125-2132
JAK/STAT Pathway Mutations
Clinical Context: Beyond 9p24.1 amplification, over 90% of Hodgkin lymphoma cases harbor mutations activating the JAK/STAT signaling pathway, creating additional therapeutic vulnerability.
JAK/STAT Alterations:
- Prevalence: >90% of classical HL cases
- Common mutations: STAT6, JAK2, SOCS1 alterations
- Pathway activation: Drives proliferation and survival of HRS cells
- Therapeutic target: JAK inhibitors (ruxolitinib)
JAK Inhibitor Combination Therapy
Evidence: Combining JAK inhibition with checkpoint blockade demonstrates clinical activity in heavily pretreated patients.
Ruxolitinib + Nivolumab Combination:
- Objective response rate: 53%
- Patient population: Relapsed/refractory after checkpoint inhibitor monotherapy
- Rationale: Dual targeting of PD-1 and JAK/STAT pathways
- Current status: Investigational; clinical trials ongoing
Reference: Zak J, Pratumchai I, Marro BS, et al. Science 2024;384:eade8520
Genomic Subtypes: H1 vs H2
Clinical Context: Molecular profiling identifies two distinct genomic subtypes of classical Hodgkin lymphoma with different mutational landscapes and biological characteristics.
| Subtype | Prevalence | Molecular Features | Clinical Characteristics |
|---|---|---|---|
| H1 subtype | 68% | STAT6 mutations, B-cell signature enrichment | May have distinct response patterns |
| H2 subtype | 32% | Alternative mutational profile, different pathway activation | Biological and potentially therapeutic differences |
Clinical Utility: Subtype classification is primarily of research interest currently, but may inform future treatment selection strategies as subtype-specific therapies emerge.
Brentuximab Vedotin: CD30-Directed Therapy
Clinical Context: While not typically assessed via ctDNA testing, CD30 (a cell surface marker) is near-universally expressed on HRS cells and represents a major therapeutic target. CD30 expression is assessed via immunohistochemistry rather than molecular profiling.
Brentuximab Vedotin Efficacy:
- Monotherapy ORR: 75% in relapsed/refractory disease
- Combination with AVD (frontline): Superior outcomes vs ABVD chemotherapy
- Combination with nivolumab: 85% ORR, 67% CR (synergistic with checkpoint blockade)
- Post-ASCT consolidation: Significantly improves PFS (HR 0.57, AETHERA trial)
Reference: Connors JM et al. N Engl J Med 2018;378:331-344
Clinical Recommendation: Genotype-Directed Therapy
9p24.1 Amplification (100% of cases):
- First-line checkpoint inhibitor indication: Consider pembrolizumab or nivolumab in relapsed/refractory setting
- Expected efficacy: 69-87% ORR as monotherapy
- Combination approach: Nivolumab + brentuximab achieves 85% ORR
JAK/STAT Pathway Activation (>90% of cases):
- Investigational approach: Ruxolitinib + checkpoint inhibitor combinations
- Current efficacy: 53% ORR in checkpoint-refractory patients
- Clinical trial consideration: For patients progressing on checkpoint monotherapy
Note: Unlike solid tumors, biomarker testing is less critical in Hodgkin lymphoma given near-universal 9p24.1 amplification. All relapsed/refractory patients are candidates for checkpoint inhibitors regardless of specific molecular profiling.
Clinical Summary
ctDNA testing in Hodgkin lymphoma demonstrates exceptional prognostic value for MRD monitoring (HR 5.3 in the full HD21 publication, Blood 2026) and reveals near-universal therapeutic targets, particularly 9p24.1 amplification enabling checkpoint inhibitor therapy. Multiple interventional trials (PRECISE-HL, Pembro-GVD) are now prospectively testing ctDNA-guided treatment decisions.
Evidence-Based Recommendations
MRD Monitoring (Strong Prognostic Value):
- Baseline detection: 92-97% sensitivity; 93.8% with targeted sequencing
- Prognostic stratification: HR 5.3 after 2 cycles (HD21 full publication, Blood 2026), 8.7 at end of treatment
- HD21 full publication: 4-year PFS 82.2% (MRD-) vs 36.7% (MRD+); combined MRD-2 + PET-2 enables three-tier risk stratification
- PET-negative/MRD-positive discordance: 3-year PFS only 36% vs 89% when both negative -- ctDNA identifies high-risk patients missed by PET
- Lead time advantage: Molecular clearance precedes radiographic response
- Interventional trials now active: PRECISE-HL (de-escalation, 125 pts) and Pembro-GVD (ASCT omission, 38 pts) testing ctDNA-guided decisions
- Clinical use: Risk stratification, clinical trial enrollment, consideration of treatment intensification or de-escalation
Molecular Profiling (Actionable Targets):
- 9p24.1 amplification (100%): PD-L1/PD-L2/JAK2 copy number gain
- Nivolumab: 87% ORR (phase 1); 69% ORR (phase 2, CheckMate 205)
- Pembrolizumab: 69% ORR
- Nivolumab + brentuximab: 85% ORR, 67% CR
- JAK/STAT mutations (>90%): Pathway activation
- Ruxolitinib + nivolumab: 53% ORR in checkpoint-refractory patients
- Genomic subtypes: H1 (68%) vs H2 (32%) with distinct molecular features
- CD30 expression: Near-universal; brentuximab vedotin achieves 75-85% ORR depending on combination
Key Limitations:
- CHIP interference: 33% of patients show clonal hematopoiesis requiring careful interpretation
- De-escalation trials active: PRECISE-HL (frontline de-escalation) and Pembro-GVD (ASCT omission) testing ctDNA-guided treatment adaptation
- Interventional validation pending: MRD identifies risk; trials are testing whether acting on MRD status improves outcomes
- Technical requirements: Highly sensitive methods needed due to low HRS cell content
Bottom Line: ctDNA testing in Hodgkin lymphoma provides exceptional prognostic information (HR 5.3 in the full HD21 publication; 4-year PFS 82.2% vs 36.7%) and reveals universal therapeutic targets (9p24.1 amplification enabling 69-87% ORR with checkpoint inhibitors). Critically, ctDNA identifies high-risk patients missed by PET (PET-negative/MRD-positive: 3-year PFS only 36%). ctDNA-guided treatment adaptation is now being actively tested in interventional trials: PRECISE-HL (frontline de-escalation, 125 patients) and Pembro-GVD (ASCT omission in R/R cHL, 38 patients). Current applications include risk stratification, combined MRD+PET assessment, treatment intensification in high-risk patients, and clinical trial enrollment.
References
- Spina V, Bruscaggin A, Cuccaro A, et al. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. Blood 2018;131:2413-2425.
- Mattlener J, Ferdinandus J, Schneider J, et al. Lymphovista HL - a Validated Assay for Genotyping and MRD Assessment in Hodgkin Lymphoma. Blood 2024;144(Supplement 1):4355.
- Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin lymphoma. N Engl J Med 2015;372:311-319.
- Chen R, Zinzani PL, Fanale MA, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol 2017;35:2125-2132.
- Zak J, Pratumchai I, Marro BS, et al. JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma. Science 2024;384:eade8520.
- Connors JM, Jurczak W, Straus DJ, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin lymphoma. N Engl J Med 2018;378:331-344.
- Heger JM, Mattlener J, Kaul H, et al. MRD-2 in the GHSG HD21 trial assessed by a validated circulating tumor DNA sequencing assay. Blood 2026. doi:10.1182/blood.2025031089.
- Ultrasensitive circulating tumor DNA MRD status predicts treatment failure and complements PET/CT throughout treatment for early and advanced stage classic Hodgkin lymphoma. ASH 2024; Abstract 201877.
- PRECISE-HL trial: Personalized reduction of chemotherapy intensity through ctDNA evaluation in advanced Hodgkin lymphoma. Blood 2025;146(Supplement 1):5408. ClinicalTrials.gov identifier pending.
- Pembrolizumab + GVD with ctDNA-guided consolidation for relapsed/refractory classic Hodgkin lymphoma: a multicenter phase 2 study. Blood 2025;146(Supplement 1):3630. ClinicalTrials.gov: NCT07021989.
- Circulating tumor DNA sequencing for biologic classification and individualized risk stratification in patients with Hodgkin lymphoma. J Clin Oncol 2024. doi:10.1200/JCO.23.01867.
Evidence summary current through April 2026 | Version 3.1
This educational resource incorporates the latest clinical trial data for ctDNA testing in Hodgkin lymphoma
Related Cancer Types
Explore ctDNA and liquid biopsy evidence for related cancer types: